Regeneron completed the acquisition of Checkmate Pharmaceuticals for $250m.

Regeneron, a biopharmaceutical company, completed the acquisition of Checkmate Pharmaceuticals, a clinical-stage biotechnology company, for $250m. "As we continue to deepen and expand our efforts in immuno-oncology, the acquisition of Checkmate adds a potentially best-in-class clinical asset, as well as a promising underlying technology platform in the VLP delivery system. Our increasingly diverse portfolio enables strategic flexibility and creativity as we advance monotherapy and combination candidates for difficult-to-treat cancers. With Libtayo as our anti-PD-1 backbone and a differentiated scientific approach, Regeneron is well positioned to make meaningful progress for people with cancer," Leonard S. Schleifer, Regeneron President and CEO.